Valuation: Unicycive Therapeutics, Inc.

Market Cap 12Cr 10Cr 9.74Cr 8.88Cr 17Cr 1.13TCr 17Cr 118.05Cr 46Cr 577.25Cr 44Cr 43Cr 1.86TCr P/E 2026 *
-3.33x
P/E 2027 * 2.3x
Enterprise Value 12Cr 10Cr 9.74Cr 8.88Cr 17Cr 1.13TCr 17Cr 118.05Cr 46Cr 577.25Cr 44Cr 43Cr 1.86TCr EV / Sales 2026 *
85.8x
EV / Sales 2027 * 0.79x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 49.3%
1 day-7.25%
1 week-10.12%
Current month-10.12%
1 month-18.69%
3 months-26.35%
6 months-39.11%
Current year-26.86%
1 week 4.09
Extreme 4.09
4.81
1 month 4.09
Extreme 4.09
5.62
Current year 3.93
Extreme 3.93
8.74
1 year 3.93
Extreme 3.93
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Free

Chief Operating Officer

1,69,500 0.6716%
14/05/26 Free

Executive/Senior Manager

1,69,500 0.6716%
14/05/26 Free

Chief Financial Officer

1,69,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
-7.25%-10.12%-8.66%-54.13% 12Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.93%-1.54%+48.08%+102.84% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+58.74%+129.85%

Financials

2026 *2027 *
Net sales 13.7L 12.18L 11.35L 10.35L 19.52L 13Cr 19.7L 1.38Cr 53.32L 6.73Cr 51.43L 50.32L 22Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.44TCr 22Cr 150.14Cr 58Cr 734.16Cr 56Cr 55Cr 2.36TCr
Net income -3.54Cr -3.14Cr -2.93Cr -2.67Cr -5.04Cr -340.73Cr -5.09Cr -36Cr -14Cr -173.75Cr -13Cr -13Cr -558.43Cr 5.71Cr 5.08Cr 4.73Cr 4.31Cr 8.14Cr 550.09Cr 8.22Cr 57Cr 22Cr 280.51Cr 21Cr 21Cr 901.56Cr
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
02/26/02 $4.220 -7.25% 15,10,067
01/26/01 $4.550 -3.09% 10,68,823
30/26/30 $4.695 +3.19% 8,62,705
29/26/29 $4.550 -1.94% 23,06,652
28/26/28 $4.640 -1.17% 6,01,475
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.220USD
Average target price
28.40USD
Spread / Average Target
+572.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock